Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Kidswell Bio Corporation ( (JP:4584) ) just unveiled an update.
Kidswell Bio Corporation, along with Alfresa Holdings and Chiome Bioscience, has entered into agreements for the joint development of biosimilars, aiming to expand treatment options and optimize medical costs. This collaboration, supported by the Ministry of Health, Labour and Welfare’s Subsidy Program, seeks to establish a stable domestic supply system for biosimilars and strengthen Japan’s biopharmaceutical industry by leveraging each company’s expertise in distribution, development, and research.
The most recent analyst rating on (JP:4584) stock is a Hold with a Yen249.00 price target. To see the full list of analyst forecasts on Kidswell Bio Corporation stock, see the JP:4584 Stock Forecast page.
More about Kidswell Bio Corporation
Kidswell Bio Corporation is involved in the development and supply of biosimilars, leveraging expertise in biologics to contribute to the biopharmaceutical industry. The company collaborates with other organizations to enhance the manufacturing and distribution of biosimilars in Japan.
Average Trading Volume: 2,102,259
Technical Sentiment Signal: Hold
Current Market Cap: Yen12.04B
See more insights into 4584 stock on TipRanks’ Stock Analysis page.